Jasper Therapeutics Inc. (JSPR)
NASDAQ: JSPR
· Real-Time Price · USD
5.54
-0.03 (-0.54%)
At close: Jun 13, 2025, 3:59 PM
5.45
-1.54%
After-hours: Jun 13, 2025, 05:29 PM EDT
-0.54% (1D)
| Bid | 5 |
| Market Cap | 83.15M |
| Revenue (ttm) | 1.17M |
| Net Income (ttm) | 13.73M |
| EPS (ttm) | -5.27 |
| PE Ratio (ttm) | -1.05 |
| Forward PE | -1.11 |
| Analyst | Buy |
| Ask | 5.9 |
| Volume | 142,122 |
| Avg. Volume (20D) | 195,120 |
| Open | 5.50 |
| Previous Close | 5.57 |
| Day's Range | 5.45 - 5.65 |
| 52-Week Range | 3.13 - 26.05 |
| Beta | 2.73 |
About JSPR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol JSPR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for JSPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
-60.53%
Jasper Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
6 months ago
-1.46%
Jasper Therapeutics shares are trading higher after the company announced it dosed its first patient in its Phase 1b/2a EESIAN study evaluating Briquilimab.
6 months ago · seekingalpha.com
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And AsthmaJasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved...